A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00750178
Phase
PHASE1
Status
Completed

Conditions

  • Cancer, Advanced

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • vorinostat (MK0683 ) — DRUG
    Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28 Total treatment period is 28 days

Study Details

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.

Key Dates

Start date
Nov 1, 2004
Status verified
Apr 2017
Primary completion
Aug 1, 2005
Completion
Nov 1, 2005

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A
    MK0683

Primary Outcome Measure

Safety, tolerability, and PK of MK0683 [ Time Frame: 28 Days ]

Related Studies